about
Structural basis of transcription: alpha-amanitin-RNA polymerase II cocrystal at 2.8 A resolutionSubunit architecture of general transcription factor TFIIHDeconvolution method for specific and nonspecific binding of ligand to multiprotein complex by native mass spectrometry.Structure of an RNA polymerase II preinitiation complex.Complete, 12-subunit RNA polymerase II at 4.1-A resolution: Implications for the initiation of transcriptionStructural basis of transcription: an RNA polymerase II-TFIIB cocrystal at 4.5 AngstromsStructural basis of transcription: separation of RNA from DNA by RNA polymerase IISchizosacharomyces pombe RNA polymerase II at 3.6-A resolutionStructural Basis of Transcription: Backtracked RNA Polymerase II at 3.4 Angstrom ResolutionStructure of an RNA Polymerase II-TFIIB Complex and the Transcription Initiation MechanismInitiation Complex Structure and Promoter ProofreadingStructure of the Mediator Head module bound to the carboxy-terminal domain of RNA polymerase IIStructure of a Complete Mediator-RNA Polymerase II Pre-Initiation ComplexRNA polymerase II trigger loop residues stabilize and position the incoming nucleotide triphosphate in transcription.Combining anatomic and molecularly targeted imaging in the diagnosis and surveillance of embryonal tumors of the nervous and endocrine systems in children.The utility of 99mTc depreotide compared with F-18 fluorodeoxyglucose positron emission tomography and surgical staging in patients with suspected non-small cell lung cancer.Safety and efficacy of repeat administration of samarium Sm-153 lexidronam to patients with metastatic bone pain.Safety analysis of repeated high doses of samarium-153 lexidronam in men with hormone-naive prostate cancer metastatic to bone.90Y-edotreotide for metastatic carcinoid refractory to octreotide.Structural basis of transcription: nucleotide selection by rotation in the RNA polymerase II active center.Molecular architecture of the yeast Mediator complex.Effects of intravenous amino acid administration with Y-90 DOTA-Phe1-Tyr3-Octreotide (SMT487[OctreoTher) treatment.Structural basis of transcription: role of the trigger loop in substrate specificity and catalysis.NANETS treatment guidelines: well-differentiated neuroendocrine tumors of the stomach and pancreasSynthesis and bioconjugation of 2 and 3 nm-diameter gold nanoparticlesNanoparticle imaging. Electron microscopy of gold nanoparticles at atomic resolution.Feasibility and advantage of adding (131)I-MIBG to (90)Y-DOTATOC for treatment of patients with advanced stage neuroendocrine tumors.99mTc-depreotide tumour uptake in patients with non-Hodgkin's lymphoma.Structural basis of eukaryotic gene transcription.Therapy with radiolabeled somatostatin peptide analogs for metastatic neuroendocrine tumors.AutoDrug: fully automated macromolecular crystallography workflows for fragment-based drug discovery.Phase I trial of 90Y-DOTATOC therapy in children and young adults with refractory solid tumors that express somatostatin receptorsUtility of radiolabeled somatostatin receptor analogues for staging/restaging and treatment of somatostatin receptor-positive pediatric tumors.Repeatability of gallium-68 DOTATOC positron emission tomographic imaging in neuroendocrine tumors.Diffusion of nucleoside triphosphates and role of the entry site to the RNA polymerase II active centerThe NANETS consensus guideline for the diagnosis and management of neuroendocrine tumors: well-differentiated neuroendocrine tumors of the Jejunum, Ileum, Appendix, and Cecum.Standard imaging techniques for neuroendocrine tumors.RNA polymerase II transcription: structure and mechanismArchitecture of an RNA polymerase II transcription pre-initiation complex.A Phase I pharmacokinetic and biological correlative study of oblimersen sodium (genasense, g3139), an antisense oligonucleotide to the bcl-2 mRNA, and of docetaxel in patients with hormone-refractory prostate cancer.
P50
Q24532570-0EA33506-FD7E-43FB-89D5-EC20AF1AF4A9Q24633293-4CFC33F0-D553-4BC0-B189-A448A2EA8573Q27301866-A0F1185F-2736-4A43-BB0D-3CEBD0F74330Q27318217-70AC829B-F184-497E-A76D-06B3332E4FDAQ27641250-08F8F44C-0B82-4BB5-B556-FBF8A63E00AEQ27643138-128DB738-2383-473E-9BB9-FFD7BDA30166Q27643139-3B68B985-105C-48FC-BF1A-F8000521C71CQ27655553-C98DBDB0-3B46-4178-A963-E78824E11386Q27655672-67FDB085-C1ED-4386-B6CE-2456F976772FQ27658448-96831034-EBFA-4D4A-9375-78310A7E7897Q27671177-8C2864A1-25E8-4F9D-9792-09FE93190659Q27674569-73A556F8-DA7E-4011-9D2A-663323471409Q27728022-E269C696-E8C5-482F-AEC4-FDC5DC513C26Q30496531-E8BA53D9-106B-4526-A8CA-57E74E25F838Q31160520-A29CC8C0-37A6-490F-944C-3D51D0C428FCQ33197567-39B089C1-C9CA-4814-949D-745D73C853D4Q33373585-32E1B8C9-E6F7-49A3-B4D0-6CED3F8BB4BBQ33379725-2C757656-979B-4F0E-A35B-AE2F15D13DAAQ34101554-7D546B15-A2D9-44A5-9BD6-04E20CBF3718Q34366785-A2109716-CB08-4E55-A409-2AF833A27133Q34495543-500B8FE0-03EA-4BE8-99D0-DFC30AC572EEQ34546925-58D9D3A4-6347-4907-A97A-F7F3CC9F82DBQ34585043-C49F207C-8D5C-4DFA-B171-C96A672C7503Q35001777-CF539878-E5E9-4EA3-9A24-DA652EBF5ABEQ35041456-49707845-2AE8-465F-8E1E-3F856A34736AQ35045171-9AD625F5-75AE-4933-AAEA-9073B1EC0DAFQ35675435-5E7B2A0B-B221-4858-9D14-39213C3BAC50Q35842024-0E600582-6396-4C67-BE5F-5DF5A49D553CQ36024269-9D3351D3-18BE-457D-829E-D963E16B6CEBQ36452874-535F3CDC-7732-456B-A4C5-E946232FB485Q36806971-7D827780-23F7-41A5-B2FA-E57CA0F5BC44Q37122608-736ACA16-74AB-46C7-B305-6D6D66A76214Q37151615-0F81DACD-DDF5-4E2B-A247-CC314E146D66Q37504159-427392F6-88AE-40A9-A0F2-C5581DED5411Q37714219-10ADBDCD-C74F-409D-A860-D637B070E6A3Q37776136-E0F0FAA2-5AEB-4BFC-A4E8-4A3C9A53C1D9Q37846924-B113ED5C-6260-40AF-A659-5460AFFB902AQ38045685-924EC8FB-E7F2-42E4-8135-24588DB72A05Q40082603-D9CF7998-BA8B-4F11-A7C6-76DE1FDC5E02Q40528459-C85CA019-D503-4192-A9D1-17C5346875C8
P50
description
researcher, ORCID id # 0000-0002-2768-396X
@en
wetenschapper
@nl
name
David Bushnell
@ast
David Bushnell
@en
David Bushnell
@es
David Bushnell
@nl
type
label
David Bushnell
@ast
David Bushnell
@en
David Bushnell
@es
David Bushnell
@nl
prefLabel
David Bushnell
@ast
David Bushnell
@en
David Bushnell
@es
David Bushnell
@nl
P106
P1153
7102249290
P21
P31
P496
0000-0002-2768-396X